Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
Open Access
- 30 April 2013
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 12 (4), 339-345
- https://doi.org/10.1016/s1474-4422(13)70037-1
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithmNature Biotechnology, 2011
- Lithium carbonate in amyotrophic lateral sclerosisNeurology, 2010
- Is the lithium-for-ALS genie back in the bottle?Neurology, 2010
- No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALSPLOS ONE, 2009
- Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant miceAmyotrophic Lateral Sclerosis, 2009
- Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factorsAmerican Journal of Physiology-Renal Physiology, 2005
- Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicityNeuropharmacology, 2002
- Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylationJournal of Neurochemistry, 2002
- El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2000
- Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neuronsProceedings of the National Academy of Sciences, 1999